GFP Adeno-Associated Virus ( AAV-RGDMSRE )

Efficient and specific delivery of therapeutic genes to target tissues is a crucial and so far unsolved problem in gene therapy. Among the viral vectors that can be used for gene delivery, adeno-associated virus (AAV) has received particular attention. The low frequency of random integration into the genome and the modest immune response make AAV an attractive basis for gene therapy vector design. In many clinical trials involving AAV vectors, no major safety issues have been encountered. As with almost all other gene therapy vectors, the tropism of AAV-2-derived vectors limits their use in gene transduction of certain tissues, especially when the vectors are delivered systemically. GFP AAV-RGDMSRE is a reporter AAV derived from AAV serotype 2 (AAV2), a well-characterized and frequently used serotype known for its relatively broad tropism and ability to infect both dividing and non-dividing cells. The peptide sequence RGDMSRE is inserted into the viral capsid at position I588. The RGDMSRE peptide sequence plays a key role in the selective tropism of the virus. It includes the RGD motif, which is known for its affinity for integrins, particularly those overexpressed on the surface of tumor cells. This insertion is designed to enhance the ability of the virus to bind and enter a specific subset of target cells (tumor cells).